Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 12
1981 4
1982 5
1983 5
1984 7
1985 10
1986 9
1987 12
1988 5
1989 17
1990 7
1991 9
1992 5
1993 8
1994 9
1995 6
1996 12
1997 14
1998 10
1999 14
2000 12
2001 36
2002 35
2003 38
2004 32
2005 54
2006 50
2007 58
2008 61
2009 46
2010 63
2011 59
2012 58
2013 45
2014 54
2015 58
2016 46
2017 37
2018 45
2019 14
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

992 results
Results by year
Filters applied: . Clear all
Page 1
Fenofibrate for Diabetic Retinopathy.
Stewart S, Lois N. Stewart S, et al. Asia Pac J Ophthalmol (Phila). 2018 Nov-Dec;7(6):422-426. doi: 10.22608/APO.2018288. Epub 2018 Jul 30. Asia Pac J Ophthalmol (Phila). 2018. PMID: 30058790 Review.
[Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A, Millán J, Ascaso JF, Blasco M, Díaz A, González-Santos P, Hernández-Mijares A, Mantilla T, Pedro-Botet JC, Pintó X; en nombre del Foro de la Dislipemia Aterogénica. Brea A, et al. Clin Investig Arterioscler. 2016 Nov-Dec;28(6):295-301. doi: 10.1016/j.arteri.2016.06.001. Epub 2016 Sep 5. Clin Investig Arterioscler. 2016. PMID: 27609708 Spanish.
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Tarantino N, Santoro F, Correale M, De Gennaro L, Romano S, Di Biase M, Brunetti ND. Tarantino N, et al. Drugs. 2018 Sep;78(13):1289-1296. doi: 10.1007/s40265-018-0965-8. Drugs. 2018. PMID: 30159817 Review.
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators. Elam MB, et al. JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828. JAMA Cardiol. 2017. PMID: 28030716 Free PMC article. Clinical Trial.
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group. Ishibashi S, et al. J Clin Lipidol. 2018 Jan-Feb;12(1):173-184. doi: 10.1016/j.jacl.2017.10.006. Epub 2017 Oct 28. J Clin Lipidol. 2018. PMID: 29203092 Free article. Clinical Trial.
[Management of hypertriglyceridaemia].
Scheen AJ, Wallemacq C, De Flines J, Paquot N. Scheen AJ, et al. Rev Med Liege. 2019 Mar;74(3):167-172. Rev Med Liege. 2019. PMID: 30897317 Free article. French.
992 results
Jump to page
Feedback